Astrana Health (ASTH) Set to Announce Earnings on Thursday

Astrana Health (NASDAQ:ASTH) is scheduled to issue its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of $0.33 per share for the quarter. Astrana Health has set its FY24 guidance at $1.12-1.36 EPS and its FY 2024 guidance at 1.120-1.360 EPS.Investors interested in participating in the company’s conference call can do so using this link.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.01. The company had revenue of $486.30 million during the quarter, compared to analyst estimates of $440.68 million. Astrana Health had a net margin of 4.30% and a return on equity of 10.71%. The firm’s revenue was up 39.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.28 EPS. On average, analysts expect Astrana Health to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Astrana Health Stock Performance

ASTH stock opened at $55.61 on Thursday. Astrana Health has a 1-year low of $28.86 and a 1-year high of $63.20. The business’s 50-day moving average price is $54.42 and its two-hundred day moving average price is $46.63. The firm has a market cap of $3.12 billion, a PE ratio of 42.13, a P/E/G ratio of 2.20 and a beta of 1.21. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 0.62.

Analyst Upgrades and Downgrades

Several analysts have commented on ASTH shares. KeyCorp assumed coverage on shares of Astrana Health in a report on Friday, October 11th. They set a “sector weight” rating on the stock. Stifel Nicolaus upped their target price on shares of Astrana Health from $48.00 to $60.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. BTIG Research lifted their price target on Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, October 3rd. Robert W. Baird lifted their target price on Astrana Health from $54.00 to $67.00 and gave the company an “outperform” rating in a research report on Thursday, August 15th. Finally, TD Cowen initiated coverage on Astrana Health in a research report on Monday, October 14th. They set a “buy” rating and a $66.00 price target for the company. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $62.00.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.